Yazar "Arak, Hacı" için listeleme
-
Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer
İlhan, Yusuf; Tatlı, Ali Murat; Teker, Fatih; Önder, Arif Hakan; Köse, Fatih; Geredeli, Çağlayan; Karaağaç, Mustafa; Kaplan, Muhammet Ali; İnanç, Mevlüde; Göktaş Aydın, Sabin; Kargı, Ayşegül; Arak, Hacı; Özturk, Banu; Beşen, Ali Ayberk; Selvi, Oğuzhan; Korkmaz, Mustafa; Oruç, Zeynep; Bozkurt, Oktay; Bilici, Ahmet; Bayram, Selami; Dae, Shute Ailia; Özdoğan, Mustafa; Coşkun, Hasan Şenol; Sezgin Göksu, Sema (BMJ Publishing Group, 2022)OBJECTIVE: Cisplatin-paclitaxel and bevacizumab is a frequently used treatment regimen for metastatic or recurrent cervical cancer, and carboplatin-paclitaxel and bevacizumab are also among the recommended regimens. In ... -
Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study
Şenocak Taşçı, Elif; Kutlu, Yasin; Ölmez, Ömer Fatih; Mutlu, Arda Ulaş; Gündoğdu, Yasemin; Seyyar, Mustafa; Şahin, Elif; Çabuk, Devrim; Majidova, Nargiz; Uğurlu, İrem; Demirci, Ayşe; Aydın, Dinçer; Çavdar, Eyyüp; Bayram, Selami; Yıldırım, Nilgün; Karataş, Fatih; Karakurt Eryılmaz, Melek; Çağlayan, Dilek; Menekşe, Serkan; Kut, Engin; Arak, Hacı; Keser, Murat; Sunar, Veli; Perkin, Perihan; Şakalar, Teoman; Oyan, Başak; Sönmez, Özlem; Özer, Leyla; Yıldız, İbrahim (2024)Background: Triple negative breast cancer (TNBC) is characterized by high rates of recurrence, especially in patients with residual disease after neoadjuvant chemotherapy (NAC). Capecitabine is being used as standard ...